medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 6

<< Back Next >>

Ann Hepatol 2017; 16 (6)

Burden of Chronic Viral Hepatitis and Liver Cirrhosis in Brazil - the Brazilian Global Burden of Disease Study

de Carvalho JR, Villela-Nogueira CA, Perez RM, Portugal FB, Flor LR, Campos MR, Schramm JMA

Language: English
References: 36
Page: 893-900
PDF size: 182.97 Kb.


ABSTRACT

Introduction and aim. Data on epidemiology of liver diseases in Brazil is scarce. This study aimed to estimate the burden of chronic viral hepatitis and liver cirrhosis in the country. Materials and methods.The indicator used was disability-adjusted life year (DALY), a sum of years of life lost due to premature mortality (YLL) and years lived with disability (YLD). Liver cirrhosis was analyzed in etiologic categories and cirrhosis of viral origin was considered part of the burden of chronic hepatitis. Results. There were 57,380 DALYs (30.3 per 100,000 inhabitants) attributable to chronic hepatitis B and cirrhosis due to hepatitis B, with 41,262 DALYs in men. Most burden was caused by YLL (47,015 or 24.8/100,000) rather than YLD (10,365 or 5.5/100,000). Chronic hepatitis C and cirrhosis due to hepatitis C were responsible for 207,747 DALYs (109.6/100,000), of which 137,922 were YLL (72.7/100,000) and 69,825 (36.8/100,000) were YLD, with a higher proportion of DALYs in men (73.9%). Cirrhosis due to alcohol or other causes had a total of 536,169 DALYs (1,4% of total DALYs in Brazil), with 418,272 YLL (341,140 in men) and 117,897 YLD (97,965 in men). Highest DALYs' rates occurred at ages 60-69 in chronic hepatitis and at ages 45-59 in cirrhosis due to alcohol or other causes. Conclusion. Chronic viral hepatitis and liver cirrhosis are responsible for a significant burden in Brazil, affecting mainly men and individuals still in their productive years. Most burden is related to non-viral causes of cirrhosis, with a major contribution of alcohol.


REFERENCES

  1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.

  2. Kershenobich D, Razavi HA, Sanchez-Avila JF, Bessone F, Coelho HS, Dagher L, Goncales FL, et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int 2011; 31(Suppl. 2): 18-29.

  3. Bosetti C, Levi F, Lucchini F, Zatonski WA, Negri E, La Vecchia C. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 2007; 46: 827-39.

  4. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011; 31(Suppl. 2): 30-60.

  5. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, Amarapurkar D, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31(Suppl. 2): 61-80.

  6. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-128.

  7. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990- 2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 385: 117-71.

  8. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-31.

  9. de Franchis R, Dell’Era A. Non-invasive diagnosis of cirrhosis and the natural history of its complications. Best Pract Res Clin Gastroenterol 2007; 21: 3-18.

  10. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61: S58-68.

  11. McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis 2010; 14: 381-96.

  12. Cainelli F. Liver diseases in developing countries. World J Hepatol 2012; 4: 66-7.

  13. Nader LA, de Mattos AA, Bastos GA. Burden of liver disease in Brazil. Liver Int 2014; 34: 844-9.

  14. Murray CJL, Lopez AD. The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press; 1996.

  15. Leite IC, Valente JG, Schramm JM, Daumas RP, Rodrigues Rdo N, Santos Mde F, de Oliveira AF, et al. Burden of disease in Brazil and its regions, 2008. Cad Saude Publica 2015; 31: 1551-64.

  16. Ximenes RA, Pereira LM, Martelli CM, Merchan-Hamann E, Stein AT, Figueiredo GM, Braga MC, et al. Methodology of a nationwide cross-sectional survey of prevalence and epidemiological patterns of hepatitis A, B and C infection in Brazil. Cad Saude Publica 2010; 26: 1693-704.

  17. Pereira LMB, Ximenes RAA, Moreira RC, Braga MC, Montarroyos UR. Estudo de Prevalência de Base Populacional das Infecções pelos Vírus das Hepatites A, B e C. Available at: http://www.aids.gov.br/sites/default/files/anexos/publicacao/ 2010/50071/estudo_prevalencia_hepatites_pdf_26830.pdf

  18. Focaccia R, da Conceicao OJ, Sette H, Jr., Sabino E, Bassit L, Nitrini DR, Lomar AV, et al. Estimated Prevalence of Viral Hepatitis in the General Population of the Municipality of Sao Paulo, Measured by a Serologic Survey of a Stratified, Randomized and Residence-Based Population. Braz J Infect Dis 1998; 2: 269-84.

  19. Barendregt JJ, Bonneux L, Van der Maas PJ. DALYs: the age-weights on balance. Bull World Health Organ 1996; 74: 439-43.

  20. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990- 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-223.

  21. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163-96.

  22. Garcia-Fulgueiras A, Garcia-Pina R, Morant C, de Larrea-Baz NF, Alvarez E. Burden of disease related to hepatitis C and hepatitis B in Spain: a methodological challenge of an unfolding health problem. J Viral Hepat 2011; 18: e453-60.

  23. Organization WH: Global Status Report on Alcohol and Health. In: Organization WH (ed.). Geneva: World Health Organization; 2014.

  24. Gowing LR, Ali RL, Allsop S, Marsden J, Turf EE, West R, Witton J. Global statistics on addictive behaviours: 2014 status report. Addiction 2015; 110: 904-19.

  25. Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, Freedman G, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013; 382: 1564-74.

  26. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcoholuse disorders. Lancet 2009; 373: 2223-33.

  27. Portugal FB, Campos MR, de Carvalho JR, Flor LS, Schramm JM, Costa MF. Disease burden in Brazil: an investigation into alcohol and non-viral cirrhosis. Cien Saude Colet 2015; 20: 491-501.

  28. Pereira LM, Martelli CM, Moreira RC, Merchan-Hamman E, Stein AT, Cardoso MR, Figueiredo GM, et al. Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. BMC Infect Dis 2013; 13: 60.

  29. Brandao AB, Fuchs SC. Risk factors for hepatitis C virus infection among blood donors in southern Brazil: a case-control study. BMC Gastroenterol 2002; 2: 18.

  30. Codes L, de Freitas LA, Santos-Jesus R, Vivitski L, Silva LK, Trepo C, Reis MG, et al. Comparative study of hepatitis C virus genotypes 1 and 3 in Salvador, Bahia Brazil. Braz J Infect Dis 2003; 7: 409-17.

  31. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-8.

  32. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global Epidemiology of Non-Alcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence and Outcomes. Hepatology 2016; 64: 73-84.

  33. Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease - current status and future directions. J Dig Dis 2015; 16: 541-57.

  34. Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, Zuckerman E, et al. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. Liver Int 2011; 31(Suppl.): 2: 4-17.

  35. Silva L, Parana R, Mota E, Cotrim HP, Boennec-McCurtey ML, Vitvitinsky L, Padua A, et al. Prevalence of hepatitis C virus in urban and rural populations of northeast Brazil-pilot study. Arq Gastroenterol 1995; 32: 168-71.

  36. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011; 31: 1090-101.




2020     |     www.medigraphic.com